Articles tagged with Cancer Medication
Researchers at McGill University discovered a shared genetic marker that could effectively treat rare and common types of cancer, including ovarian and lung cancers. The breakthrough is based on targeting the cyclin-dependent kinases 4/6, which are vulnerable to existing drugs used in breast cancer treatment.
A recent study published in Human Reproduction found that children born after fertility treatment do not have an increased risk of developing cancer compared to those conceived naturally. However, some cancers, such as lymphoblastic leukemia and melanoma, were slightly more common in ART-conceived children, although the findings are st...
Researchers identified a crucial link between polyamines and the MYCN oncogene, revealing a new therapeutic approach to disrupt cancer cell growth. A combination therapy of DFMO and AMXT-1501 showed significant increase in survival in mice with established neuroblastoma tumours.
Scientists developed a new method to study ADP-ribosylation, a process linked to cancer growth and other diseases. The ELTA technique enables researchers to attach molecular beacons to ADP-ribose molecules, allowing for detailed studies on how this process affects cells in health and disease.
Researchers identify a new molecular pathway that suggests rapamycin, an anti-rejection medication, could be repurposed to treat certain liver cancers with β-catenin mutations. The study found that tumors are 'mTOR addicted' and can be inhibited by rapamycin, offering a precision medicine approach for improved treatment success.
A study of 28,000 childhood cancer survivors found that exposure to different anthracycline chemotherapies results in variable long-term cardiovascular risk. Specifically, daunorubicin was associated with decreased cardiomyopathy risk compared to doxorubicin, while mitoxantrone appeared to have greater long-term cardiomyopathy risk.
The Lung Cancer Master Protocol (Lung-MAP) is expanding to include patients with all types of advanced stage non-small cell lung cancers. This will allow thousands of new patients to enroll in the trial and benefit from investigational drugs, addressing a significant need for new treatments.
Drs. Silvia Formenti and Heather McArthur will collaborate on a year-long project using radiation and immunotherapy to create personalized vaccines for breast cancer patients. Their work aims to improve treatment outcomes and reduce mortality.
Scientists at CeMM Research Center have developed a method to identify promising drug combinations for chronic lymphocytic leukemia. By combining epigenetic analysis and high-throughput imaging, researchers can predict which drugs are likely to work together effectively, reducing trial-and-error approaches.
Researchers at Purdue University have developed a series of drug compounds that have shown promise in treating acute myeloid leukemia (AML), a type of blood cancer that is often lethal. The new compounds work on both common and drug-resistant forms of AML, including those with problematic mutations.
A new study found that extending medication time for varenicline to 24 weeks combined with 24 weeks of counseling sessions improves quitting success rates and reduces relapse risk in cancer patients. For those taking the medication as directed, quit rates increased significantly.
Researchers found that cancer cells switch to brute force and build a protrusion when MMP enzymes aren't available. This allows them to penetrate the basement membrane and invade other organs. The study identified a mitochondrial gene target that could be used to develop new treatments.
Shapiro's comprehensive program in early cancer drug development has provided scientific and clinical direction for multiple investigational agents. His work has contributed to the advancement of several approved drugs, including CDK4/6 inhibitors.
A new test for pediatric tumour analysis has been developed that may provide faster diagnosis times and more accurate genetic mutation detection. The test uses DNA sequencing technology to identify weaknesses in tumor cells that can be targeted with drugs, offering potential improvements in treatment options for children with cancer.
Researchers have discovered a promising new drug that targets the biological clock of cancer cells, slowing their growth and halting their spread. By disrupting the circadian rhythm of cancer cells, this drug may provide an effective new treatment option for various types of cancer.
Finasteride has been shown to reduce the risk of prostate cancer by 25 percent, with no significant increase in mortality rates. The study's findings have eliminated concerns over initial reports of potential risks, and doctors are now recommending finasteride as a preventive strategy for prostate cancer.
Researchers at University College London have discovered the genetic differences between lung cancer precursor cells and harmless lesions. This breakthrough could lead to the development of screening tests and new treatments that can stop cancer in its tracks, saving lives by detecting the disease earlier.
Researchers at University at Buffalo received an $880,000 grant to develop a model of the female reproductive tract for testing drugs delivered vaginally or to the uterus. This project aims to create cost-effective generic equivalents for existing medications, addressing the limited availability of affordable treatment options.
Researchers uncover potent and selective inhibitor of SHP2, a key target for cancer treatment. The discovery could lead to improved cancer drugs and new strategies for killing cancer cells.
SYNB1020, Synlogic's Synthetic Biotic medicine, demonstrates safety and proof of mechanism in healthy volunteers, clearing ammonia from the blood. The therapy is being evaluated in patients with cirrhosis and elevated blood ammonia, offering a potential new treatment for hyperammonemia.
Researchers at Columbia University have developed a chemical process to convert infrared light to visible energy, allowing innocuous radiation to penetrate living tissue without damaging it. This technology holds promise for enhancing the effectiveness of photodynamic therapy in treating various diseases.
Losartan reduces extracellular matrix content and solid stress in ovarian tumors, increasing blood supply and drug delivery. The addition of losartan to chemotherapy agents could improve outcomes for patients with ovarian cancer.
Researchers develop a novel approach to target aggressive liver cancer by inhibiting protein production, leaving healthy cells unharmed. The study shows promising results using a genetic approach and a drug that directly inhibits translation, slowing tumor growth and blocking immune evasion.
A landmark study published in the New England Journal of Medicine has found that ibrutinib is significantly more effective than standard therapy in treating CLL, causing fewer side effects and requiring less frequent patient visits. Ibrutinib was shown to improve survival rates by 13% compared to standard treatment.
A team of researchers at the University of Zurich has determined the three-dimensional structure of the receptor that causes nausea and vomiting as a result of cancer chemotherapy. They found that effective drugs like EmendTM and AkynzeoTM alter the receptor's structure, allowing for long-lasting attachment and effective treatment.
Researchers at Emory University have developed a high-throughput screening platform to identify small molecules that can enhance the ability of human immune cells to kill cancer cells. The platform, called HTiP, has identified compounds such as birinapant, which has shown strong evidence for its relevance as an immune enhancer.
Researchers have developed a 'drug sponge' that can absorb up to 64% of chemotherapy drugs from the bloodstream, potentially reducing toxic side effects. The technology uses an absorbent polymer coating on a 3D-printed cylinder inserted into a vein, which sops up excess drugs before they reach other organs.
Scientists have created a 3D-printed device that can absorb excess chemotherapy drugs from a patient's bloodstream before they spread to healthy cells. The device captured about 64% of doxorubicin, a commonly used chemotherapy drug, reducing the likelihood of side effects such as hair loss and nausea.
A Dartmouth-led study reveals that exposure to sugary breakfast cereal advertising directly influences children's diets, leading to increased intake of those cereals. The research suggests a concerning link between child-directed high-sugar cereal TV advertising and brand-specific cereal consumption among preschoolers.
The Polsky Urologic Cancer Institute will provide personalized, integrated, and innovative care to individuals with urologic cancers through a disease-centric program of research, education, and discovery. The institute aims to transform how urologic cancers are treated in Chicago and worldwide.
Researchers have discovered a new way to boost the immune system's attack on cancer cells by blocking a routine cell mechanism. This breakthrough has shown promising results in lung and melanoma cancers, offering a potential solution for treating a large number of patients.
Researchers at MIT have developed an inhalable form of messenger RNA that can be delivered directly to the lungs, showing promise for treating various lung diseases. The aerosol-formulated mRNA was found to induce lung cells in mice to produce a target protein, paving the way for potential treatments.
The Mark Foundation has awarded grants to eight promising early career scientists pursuing innovative projects in cancer risk prediction, prevention, detection, and treatment. The recipients aim to tackle diverse areas of basic, translational, and early clinical cancer research.
A recent study has found that standard treatment for glioblastoma is more effective in women than men, with tumor growth velocity showing a steady decline after treatment. The researchers identified distinct molecular signatures of the disease in men and women, which could lead to sex-specific treatment strategies.
Recent advances in computational methods enhance the accuracy and reproducibility of label-free quantification (LFQ) in cancer proteomics, enabling discovery of anti-cancer targets and drugs. The study evaluates popular acquisition techniques and state-of-the-art quantification tools to improve LFQ performance.
A study using monkeys with the breast cancer drug letrozole found significant behavioral changes and impaired brain function, including hot flashes, increased anxiety, and spatial memory issues. The research highlights the importance of studying the effects of estrogen-reducing treatments on the nervous system.
Northwestern University scientists discovered two successful therapies that slowed pediatric leukemia progression in mice, according to recent studies. The research focused on stabilizing the MLL protein, which can slow cancer growth and increase survival rates.
Case Western Reserve University researcher Sanjay Gupta has been awarded nearly $1 million to investigate drug resistance mechanisms in prostate cancer. He will test two promising medications, simvastatin and metformin, to overcome drug resistance and halt metastasis.
A Columbia professor has developed a predictive computer platform that analyzes all tumor types and predicts effective treatment options. The platform, OncoTreat, is based on advanced data science techniques, including information theory and ray-tracing.
The review examines chemotherapeutic drugs that bind to plasma proteins, such as cisplatin, 5-fluorouracil, and ruthenium-based compounds. These drugs interact with key plasma protease inhibitors, altering their function and inactivating them.
Researchers discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, indicating a possible pathway for treatment. The approach has promise for patients who are or become resistant to immunotherapy drugs after a recurrence of their tumors.
Research identifies chain reaction in cells that helps cancer survive BRAF and MEK treatment. A new process called ER translocation connects two common resistance mechanisms, increasing autophagy and drug resistance.
A new study has found that long-term therapy with lenalidomide doubles remission duration and improves survival in younger patients by almost 8%. The treatment is also shown to prolong the average remission time by more than two years in younger patients.
Researchers identify DPYSL3 as a molecule whose expression is altered in Claudin-Low triple-negative breast cancer, a highly metastatic and aggressive subtype. The study suggests that targeting the connection between DPYSL3 and vimentin could lead to new treatments for this disease.
Researchers found that metformin and syrosingopine combination blocks critical energy production step, driving cancer cells to death. The duo targets NAD+ regeneration, preventing lactate export and leading to cell demise.
Researchers found that anti-PD-1 therapy induces CD8+ T cells to produce interferon-gamma, which activates dendritic cells to produce IL-12, a potent activating signal. This interaction improves the efficacy of anti-PD-1 therapies and offers potential ways to broaden their application.
A novel tool has been developed to identify genetic changes in Lynch syndrome genes associated with disease symptoms. The tool, combining laboratory test results with computer-based modeling and clinical data, achieves an accuracy of about 97 percent, making it suitable for clinical use.
David Cheresh, a renowned cancer researcher, has received a $4.2 million NCI award to investigate how tumors adapt to stress and develop drug resistance. His research aims to find ways to perturb the malignant cell version of wound repair, potentially eliminating highly drug-resistant cancers.
The study discovered fractal characteristics in gene expression, enabling the prediction of gene-to-gene interactions. This knowledge can help scientists engineer cells to perform specific tasks, such as drug delivery for cancer treatment.
A new EU Horizon 2020 project aims to produce therapeutic substances in baker's yeast, providing an eco-friendly alternative to traditional methods. Researchers will map the biosynthetic pathways of Indian snakeroot to create a sustainable production route.
A recent study presented at EuroEcho-Imaging 2018 suggests that breast cancer patients who take the beta-blocker carvedilol together with trastuzumab have better-preserved left ventricular function compared to those who take trastuzumab alone. This may indicate that carvedilol can help prevent heart damage caused by trastuzumab treatment.
A study by Baylor College of Medicine researchers found that when Dna2 is absent, small DNA fragments insert themselves into chromosome breaks, leading to genomic instability. This mechanism may contribute to cancer development and other cellular conditions.
A new study optimizes drug dose sizes available, reducing pharmaceutical wastage by as much as 50% in some cases. This can help cut drug manufacturer's costs and make medicines more accessible to patients.
Researchers at SWOG share findings from three studies on breast cancer subtypes, treatment response, and recurrence. The studies used existing trial data to identify subsets of patients and tumors with distinct characteristics, which can inform treatment decisions.
A new study identifies Frizzled 5 as a promising target for developing drugs against cancer, cardiovascular disease, and fibrosis. The receptor's activation in the cell membrane triggers specific processes within the cell, making it an attractive target for future drug development.
A new combined action drug was developed by Russian scientists using ionizing radiation and bacterial toxin, showing a 2,200 times stronger effect than separate use. The drug selectively targets tumor cells and facilitates visualization of tumors, making it a diagnostic tool for cancer treatment.
A study found that older adults with heart failure who take five or more medications are at higher risk for cognitive impairment and difficulty performing daily activities. The researchers suggest that healthcare providers should consider these limitations when prescribing medications, as they may unnecessarily expose patients to incre...
A new combination therapy involving ipilimumab, nivolumab, and brentuximab vedotin safely reduces tumor size or spread in 95% of patients with recurrent Hodgkin lymphoma, achieving complete remission in 16 patients.
A recent study found that around 72% of women at higher risk of breast cancer are worried about the long-term effects of tamoxifen, while 57% believe it will give them unpleasant side-effects. Despite its proven ability to prevent breast cancer, fewer than 15% of women with discussed preventive therapy are taking tamoxifen.
Researchers found that checkpoint blockade therapy can sensitize patients to better respond to future use of drugs, even when initial attempts failed. This breakthrough has significant implications for treating relapsing non-Hodgkin lymphoma and Hodgkin lymphoma patients.